Diabetes Clinical Trials in Tucson, AZ

25 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Phase 3	Eli Lilly and Company	3 mi
DFC 004 Biomarkers for Active Diabetic Foot Ulcers	—	University of Michigan	3 mi
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes	Phase 3	Eli Lilly and Company	3 mi
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)	Phase 1/2	COUR Pharmaceutical Development Company, Inc.	3 mi
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity	Phase 3	Eli Lilly and Company	3 mi
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes	Phase 2	Hoffmann-La Roche	3 mi
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial	Phase 2	Jason Sperry	3 mi
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial	N/A	Sonavex, Inc.	3 mi
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease	Phase 3	Boehringer Ingelheim	3 mi
Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers	N/A	LifeNet Health	3 mi
Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers	N/A	Piomic Medical	3 mi
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes	Phase 3	Eli Lilly and Company	3 mi
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease	Phase 3	Prokidney	3 mi
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)	Phase 3	Eli Lilly and Company	3 mi
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin	Phase 2	Eli Lilly and Company	3 mi
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin	Phase 3	Eli Lilly and Company	3 mi
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes	Phase 3	Eli Lilly and Company	3 mi
Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence	—	University of Pittsburgh	3 mi
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)	Phase 2	Sparrow Pharmaceuticals	3 mi
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide	Phase 3	Novo Nordisk A/S	3 mi
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)	Phase 3	Viking Therapeutics, Inc.	3 mi
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes	Phase 2	Eli Lilly and Company	3 mi
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes	Phase 4	VA Office of Research and Development	3 mi
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	Phase 2/3	CSL Behring	3 mi
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events	N/A	Cleerly, Inc.	3 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.